Spectrascience New Cash Flow From Operations vs. Total Debt

Based on the key profitability measurements obtained from Spectrascience New's financial statements, Spectrascience New may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Spectrascience New's ability to earn profits and add value for shareholders. At present, Spectrascience New's EV To Sales is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 228.44, whereas Operating Cash Flow Sales Ratio is projected to grow to (320.90). The current year's Change To Netincome is expected to grow to about 1.6 M, whereas Income Before Tax is forecasted to decline to (4.2 M).
For Spectrascience New profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Spectrascience New to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Spectrascience New utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Spectrascience New's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Spectrascience New over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
For information on how to trade Spectrascience Stock refer to our How to Trade Spectrascience Stock guide.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spectrascience New. If investors know Spectrascience will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spectrascience New listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.01)
Return On Assets
(0.92)
The market value of Spectrascience New is measured differently than its book value, which is the value of Spectrascience that is recorded on the company's balance sheet. Investors also form their own opinion of Spectrascience New's value that differs from its market value or its book value, called intrinsic value, which is Spectrascience New's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spectrascience New's market value can be influenced by many factors that don't directly affect Spectrascience New's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spectrascience New's value and its price as these two are different measures arrived at by different means. Investors typically determine if Spectrascience New is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spectrascience New's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Spectrascience New Total Debt vs. Cash Flow From Operations Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Spectrascience New's current stock value. Our valuation model uses many indicators to compare Spectrascience New value to that of its competitors to determine the firm's financial worth.
Spectrascience New is currently regarded as top stock in cash flow from operations category among its peers. It also is currently regarded number one company in total debt category among its peers . As of December 4, 2024, Total Debt To Capitalization is expected to decline to -2.95. Comparative valuation analysis is a catch-all technique that is used if you cannot value Spectrascience New by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Spectrascience Total Debt vs. Cash Flow From Operations

Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Spectrascience New

Operating Cash Flow

 = 

EBITDA

-

Taxes

 = 
(1.51 M)
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Spectrascience New

Total Debt

 = 

Bonds

+

Notes

 = 
6.38 M
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Spectrascience Total Debt vs Competition

Spectrascience New is currently regarded number one company in total debt category among its peers. Total debt of Health Care industry is at this time estimated at about 12.7 Million. Spectrascience New totals roughly 6.38 Million in total debt claiming about 50% of equities under Health Care industry.
Total debt  Workforce  Valuation  Revenue  Capitalization

Spectrascience New Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Spectrascience New, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Spectrascience New will eventually generate negative long term returns. The profitability progress is the general direction of Spectrascience New's change in net profit over the period of time. It can combine multiple indicators of Spectrascience New, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Income Before Tax-4 M-4.2 M
Net Loss-4 M-4.2 M
Net Loss-4 M-4.2 M
Operating Income-2.8 M-3 M
Net Loss-4 M-4.2 M
Total Other Income Expense Net-780.7 K-819.8 K
Net Interest Income-1 M-1.1 M
Change To Netincome1.5 M1.6 M
Net Loss(0.01)(0.01)
Income Quality 0.39  0.37 
Net Income Per E B T 0.90  0.75 

Spectrascience Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Spectrascience New. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Spectrascience New position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Spectrascience New's important profitability drivers and their relationship over time.

Use Spectrascience New in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spectrascience New position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spectrascience New will appreciate offsetting losses from the drop in the long position's value.

Spectrascience New Pair Trading

Spectrascience New Pair Trading Analysis

The ability to find closely correlated positions to Spectrascience New could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spectrascience New when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spectrascience New - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spectrascience New to buy it.
The correlation of Spectrascience New is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spectrascience New moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spectrascience New moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spectrascience New can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Spectrascience New position

In addition to having Spectrascience New in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Giant Impact Thematic Idea Now

Giant Impact
Giant Impact Theme
An experimental equal-weighted decomposition of large high potential stocks based on Macroaxis scoring framework. The Giant Impact theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Giant Impact Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Spectrascience New is a strong investment it is important to analyze Spectrascience New's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spectrascience New's future performance. For an informed investment choice regarding Spectrascience Stock, refer to the following important reports:
Check out World Market Map.
For information on how to trade Spectrascience Stock refer to our How to Trade Spectrascience Stock guide.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
To fully project Spectrascience New's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Spectrascience New at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Spectrascience New's income statement, its balance sheet, and the statement of cash flows.
Potential Spectrascience New investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Spectrascience New investors may work on each financial statement separately, they are all related. The changes in Spectrascience New's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Spectrascience New's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.